EU/3/14/1359: Orphan designation for the treatment of mucopolysaccharidosis type I
pentosan polysulfate sodium
Table of contents
Overview
On 19 November 2014, orphan designation (EU/3/14/1359) was granted by the European Commission to Plexcera Therapeutics EU Limited, Ireland, for pentosan polysulfate sodium for the treatment of mucopolysaccharidosis type I.
Key facts
Active substance |
pentosan polysulfate sodium
|
Intended use |
Treatment of mucopolysaccharidosis type I
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1359
|
Date of designation |
19/11/2014
|
Sponsor |
Paradigm Biopharmaceuticals (Ireland) Limited |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
December 2022 | The sponsor's address was updated. |
November 2019 | The sponsorship was transferred to Paradigm Biopharmaceuticals (Ireland) Limited. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: